The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Tumor-related and treatment-related colostomy-free survival (CFS) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance 5FU/CisP chemotherapy (CT) in squamous cell carcinoma of the anus (SCCA): Results of ACT II.
Robert Glynne-Jones
No relevant relationships to disclose
Latha Kadalayil
No relevant relationships to disclose
Helen Meadows
No relevant relationships to disclose
David Cunningham
No relevant relationships to disclose
Leslie M. Samuel
No relevant relationships to disclose
Ian Geh
Consultant or Advisory Role - Roche
Honoraria - Merck; Novartis; Sanofi
Charles Lowdell
No relevant relationships to disclose
Roger David James
No relevant relationships to disclose
Sandy Beare
No relevant relationships to disclose
Rubina Begum
No relevant relationships to disclose
Jonathan A. Ledermann
No relevant relationships to disclose
David Sebag-Montefiore
No relevant relationships to disclose